IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, has announced its participation in the upcoming 2024 BTIG Virtual Biotechnology Conference. The event is scheduled for Monday, August 5th, 2024 at 10:00 AM ET.

The conference will feature a fireside chat with Yujiro S. Hata, Chief Executive Officer of IDEAYA Biosciences, hosted by Justin Zelin, Director of Biotechnology Research Analysis at BTIG. This virtual event provides an opportunity for investors to gain insights into IDEAYA's latest developments in targeted therapeutics for oncology.

A live audio webcast of the conference event will be made available through the conference host, allowing interested parties to tune in remotely.

SOUTH SAN FRANCISCO, Calif., July 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations event.

2024 BTIG Virtual Biotechnology Conference
Monday, August 5^th, 2024 at 10:00 AM ET

• Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Justin Zelin, Director, Biotechnology Research Analyst

A live audio webcast of the conference event will be available through the conference host.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.  IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies.  IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets. 

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 20, 2024.

Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-august-2024-investor-relations-event-302207926.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

When is IDEAYA Biosciences (IDYA) participating in the BTIG Virtual Biotechnology Conference?

IDEAYA Biosciences (IDYA) is participating in the 2024 BTIG Virtual Biotechnology Conference on Monday, August 5th, 2024 at 10:00 AM ET.

Who will represent IDEAYA Biosciences (IDYA) at the BTIG Virtual Biotechnology Conference?

Yujiro S. Hata, the Chief Executive Officer of IDEAYA Biosciences, will represent the company in a fireside chat at the conference.

Will there be a webcast available for IDEAYA Biosciences' (IDYA) presentation at the BTIG conference?

Yes, a live audio webcast of IDEAYA Biosciences' (IDYA) presentation at the BTIG Virtual Biotechnology Conference will be available through the conference host.

What is the focus of IDEAYA Biosciences (IDYA) as a company?

IDEAYA Biosciences (IDYA) is a precision medicine oncology company committed to the discovery and development of targeted therapeutics.